Davis will lead comms for AstraZeneca

Share this article:
AstraZeneca named the AARP's Lisa Davis, a long-time Washington communications hand, to head all internal and external corporate communications in the US.

Davis, who becomes VP, corporate communications, a new position, heads a team of 30 and reports to David Nicoli, VP corporate affairs. She was head of PR and communications for AARP, where she worked with healthcare PR pioneer Bill Novelli, founder of Porter Novelli and current AARP CEO. She was national deputy press secretary for President Clinton's re-election campaign in 1996, and from 1993-1996, she served as press secretary for the Democratic Leadership Council and the Progressive Policy Institute.

Davis will head implementation of a corporate reputation campaign for the firm. "AstraZeneca has a great story to tell, and we want to be able to tell that to a broader audience," she said. "People know a lot about our products but they know a lot less about the company." Edelman, will assist on the campaign.

"We have an industry that is, by nature, a white hat industry," she said. "Our scientists get up every day and try to figure out how to help someone's health problem. That's a noble goal, and somewhere along the way, people stopped knowing that."

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...